Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Multitargeting interfering RNAs having two active strands and methods for their design and use

a multi-targeting, interfering technology, applied in the direction of viruses/bacteriophages, genetic material ingredients, drug compositions, etc., can solve the problems of reducing the therapeutic effect of single target inhibition, unable to achieve therapeutic efficacy, so as to reduce stress or inflammatory response, increase or decrease the modulation of expression

Inactive Publication Date: 2007-11-22
JOHNSON & JOHNSON RES PTY LTD
View PDF0 Cites 57 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028] The designing methods of this invention may further comprise the step of modifying the multitargeting interfering RNA molecule, i) to improve the incorporation of the first and the second strands of the multitargeting interfering RNA molecule into the RNA induced silencing complex (RISC); ii) to increase or decrease the modulation of the expression of at least one target RNA molecule; iii) to decrease stress or inflammatory response when the multitargeting interfering RNA molecule is administered into a subject; iv) to alter half life in an expression system; or v) any combination of i) to iv).

Problems solved by technology

Thus, the use of single-gene targeting approaches may not succeed except where a single or dominant pathophysiologic pathway can be identified and interrupted.
Attempts to confirm that inhibiting single targets in isolation is therapeutically valuable have been disappointing.
Indeed, obtaining therapeutic effectiveness is proving to be extremely challenging, probably because of multiple levels of redundancy in most signaling pathways.
For example, therapeutic approaches to viral infections continue to be major challenges in agriculture, as well as in animal and human health.
Furthermore, although nucleic acid therapeutics such as interfering RNAs are candidates for viral therapy, in part because modern rapid gene sequencing techniques allow viral genome sequences to be determined even before any encoded functions can be assessed, the error-prone replication of viruses, particularly RNA viruses, means that substantial genomic diversity can arise rapidly in an infected population.
It is unclear whether these constructs are efficient at treating viral infection or preventing emergence of resistant viral clones.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multitargeting interfering RNAs having two active strands and methods for their design and use
  • Multitargeting interfering RNAs having two active strands and methods for their design and use
  • Multitargeting interfering RNAs having two active strands and methods for their design and use

Examples

Experimental program
Comparison scheme
Effect test

example 1

CODEMIRs to VEGF-A and ICAM-1

[0236] Approaches for the design of multi-targeting of ICAM-1 and VEGF-A with CODEMIRs were considered.

[0237] The entire mRNA sequence for each of VEGF-A and ICAM-1 was used. These sequences were searched to find sequences that are present in the coding strand for one target and the complement of the coding strand for another target. Here, the sequence 5′-AGTGACTGTCAC-3′ (SEQ ID NO: 1) was identified both in the ICAM-1 coding sequence and in the complement of the VEGF-A coding sequence. This sequence was used to design a CODEMIR active against multiple targets, using each strand of the CODEMIR to target at least one of the target RNAs. The sequence identified above and its complement were used as a centrally-located part of a CODEMIR duplex. Each strand of this central duplex was extended in the 5′ direction to provide full complementarity to the corresponding target, whereas each strand was extended in the 3′ direction so as to be complementary to its...

example 2

CODEMIRs to Gluc6P and Inppl1

[0249] CODEMIRs may also be suitable for the treatment of complex metabolic diseases such as type 2 diabetes. Two potential gene targets for the treatment of this disease are glucose-6-phosphatase and Inppl1. Full transcript sequences were examined. Candidate CODEMIRs from the best contiguous region of identity are shown for each case in Table 2-1.

[0250] Regions of complementarity between the two targets were found and the two identified seeds (Table 2-1: CUGCCUCGCCCAG (SEQ ID NO: 19) and CUCCACAUCCAC) (SEQ ID NO: 20) were used as the central motifs for two possible CODEMIR duplexes. The latter seed and its complement were extended at their 5′ ends to generate duplexes in which each strand has 5′ complementarity to one of the target sequences (FIG. 2A). This is important because both strands of the CODEMIR duplex are effectors and an increased region of identity of each strand with its target needs to be extended to the 5′ terminus, whereas the less cr...

example 3

VIROMIRs Targeting Multiple Sites Within the HIV Genome

[0252] The invention can be used to target proteins of interest that are likely to be mutated in chronic forms of disease. Mutations may be particularly prevalent in cancer and viral disease in which drug-resistant forms often evolve. In this example, VIROMIRs were designed to target multiple sites in the Human Immunodeficiency Virus (HIV). The requirement for simultaneous mutation at several sites, in order to overcome the effects of such a VIROMIR, is likely to provide a high genetic hurdle to the emergence of resistant viral clones or quasispecies. The genome of the HXB2 strain of HIV I serotype B (GenBank Accession K03455) was used as the principal sequence of interest and was examined with bioinformatics methods detailed elsewhere in this application to find seeds occurring at more than one location. All HIV I clade B isolates in the LANL database as of 1 Aug. 2005 which contain full sequences for any of the GAG, ENV, POL,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
sizeaaaaaaaaaa
step sizeaaaaaaaaaa
Login to View More

Abstract

Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are used to modulate expression of the target sequences. The multitargeting interfering RNA molecules have two strands that target multiple target sites on one or more pre-selected RNA molecules. Such a multitargeting interfering RNA approach provides a powerful tool for gene regulation.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Patent Application Nos. 60 / 738,441 filed Nov. 21, 2005 and 60 / 738,640 filed Nov. 21, 2005, respectively, which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION [0002] The present invention concerns methods and reagents useful in modulating gene expression. Particularly, the invention relates to modulating gene expression using one multitargeting interfering RNA molecule having two strands each of which targets one or more sites on one or more pre-selected RNA molecules. BACKGROUND OF THE INVENTION [0003] It is now known that single and double-stranded RNA can modulate expression of or modify processing of target RNA molecules by a number of mechanisms. Some such mechanisms tolerate variation in the amount of sequence complementarity required between the modulatory (or interfering) RNA and the target RNA. Certain microRNAs can translationally repress tar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C07H21/04C07H21/02A01H5/00
CPCA61K31/7105A61K31/7115A61K31/712A61K31/713C12N15/111C12N2320/50C12N15/1132C12N15/1135C12N15/1136C12N15/1138C12N2310/14C12N15/113A61P11/00A61P31/12A61P31/14A61P31/16A61P31/18A61P43/00
Inventor RIVORY, LAURENT PIERREPOIDINGER, MICHAELBIRKETT, DONALD JOHNARNDT, GREGORY MARTINPASSIOURA, TOBY
Owner JOHNSON & JOHNSON RES PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products